유레아플라즈마에 대해 출생 전 및 출생 후 예방적 마크로라이드 치료가 미숙아의 기관지폐형성이상의 발생에 미치는 영향
Effect of Prenatal and Postnatal Prophylaxis with Macrolide for Ureaplasma on the Development of Bronchopulmonary Dysplasia in Preterm Infants
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: We aimed to evaluate the effects of two different macrolide prophylaxis protocols (prenatal and postnatal) for Ureaplasma on the development of bronchopulmonary dysplasia (BPD). Methods: We retrospectively reviewed the medical charts of 121 preterm infants whose birth weights were <1,250 g or gestational ages were <30 postmenstrual weeks. The demographic and clinical characteristics, including the presence of BPD, were compared between a prophylactic group, who received macrolide as prophylaxis prenatally and postnatally according to risk level, and a confirmed treatment group, who received macrolide prenatally and postnatally after detection of Ureaplasma infection. Results: Seventy-four (61.2%) of 121 preterm infants were included in the prenatal prophylaxis group. No significant differences in demographic characteristics were observed between the prenatal prophylaxis and prenatal confirmed treatment group. The detection rate of Ureaplasma and the frequency of postnatal therapeutic treatment with macrolide were lower in the prenatal prophylaxis group than in the prenatal confirmed treatment group (16.2% vs. 40.4%, P=0.003; 8.1% vs. 48.9%, P< 0.001, respectively). Although no significant differences in the incidence of moderate to severe BPD, the rate of severe BPD was lower in the prenatal prophylaxis group than in prenatal confirmed treatment group (18.9% vs. 40.4%, P=0.010). No significant differences in the incidences of BPD of any level of severity were observed between the postnatal prophylaxis and confirmed treatment groups. Conclusion: Administration of prenatal prophylaxis with macrolide decreased the detection rate of Ureaplasma after birth and was associated with the decrease in the incidence of severe BPD in preterm infants.
Abstract
Purpose: We aimed to evaluate the effects of two different macrolide prophylaxis protocols (prenatal and postnatal) for Ureaplasma on the development of bronchopulmonary dysplasia (BPD). Methods: We retrospectively reviewed the medical charts of 121 preterm infants whose birth weights were <1,250 g or gestational ages were <30 postmenstrual weeks. The demographic and clinical characteristics, including the presence of BPD, were compared between a prophylactic group, who received macrolide as prophylaxis prenatally and postnatally according to risk level, and a confirmed treatment group, who received macrolide prenatally and postnatally after detection of Ureaplasma infection. Results: Seventy-four (61.2%) of 121 preterm infants were included in the prenatal prophylaxis group. No significant differences in demographic characteristics were observed between the prenatal prophylaxis and prenatal confirmed treatment group. The detection rate of Ureaplasma and the frequency of postnatal therapeutic treatment with macrolide were lower in the prenatal prophylaxis group than in the prenatal confirmed treatment group (16.2% vs. 40.4%, P=0.003; 8.1% vs. 48.9%, P< 0.001, respectively). Although no significant differences in the incidence of moderate to severe BPD, the rate of severe BPD was lower in the prenatal prophylaxis group than in prenatal confirmed treatment group (18.9% vs. 40.4%, P=0.010). No significant differences in the incidences of BPD of any level of severity were observed between the postnatal prophylaxis and confirmed treatment groups. Conclusion: Administration of prenatal prophylaxis with macrolide decreased the detection rate of Ureaplasma after birth and was associated with the decrease in the incidence of severe BPD in preterm infants.
참고문헌 (28)
- Jobe AH, "Antenatal associations with lung maturation and infection", J Perinatol, 25(Suppl 2), pp.S31~35 (2005)
- 최창원, "기관지폐이형성증의 역학, 임상양상 및 병태생리", Neonatal medicine, 20(3), pp.281~289 (2013), 대한신생아학회
- Speer CP, "Inflammation and bronchopulmonary dysplasia: a continuing story", Semin Fetal Neonatal Med, 11, pp.354~362 (2006)
- Cassell GH, "Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns", Clin Microbiol Rev, 6, pp.69~87 (1993)
- Waites KB, "Mycoplasmas and ureaplasmas as neonatal pathogens", Clin Microbiol Rev, 18, pp.757~789 (2005)
- Viscardi RM, "Ureaplasma species: role in neonatal morbidities and outcomes", Arch Dis Child Fetal Neonatal Ed, 99, pp.F87~92 (2014)
- Viscardi RM, "Role of Ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence", Pediatr Res, 65, pp.84R~90R (2009)
- Lowe J, "Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis", Pediatr Infect Dis J, 33, pp.697~702 (2014)
- Nair V, "Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis", Neonatology, 106, pp.337~347 (2014)
- Calleri LF, "Ureaplasma urealyticum vaginosis and premature rupture of membranes. What is its role?", Minerva Ginecol, 52, pp.49~58 (2000)
- Jobe AH, "Bronchopulmonary dysplasia", Am J Respir Crit Care Med, 163, pp.1723~1729 (2001)
- Bell MJ, "Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging", Ann Surg, 187, pp.1~7 (1978)
- Bührer C, "Role of erythromycin for treatment of incipient chronic lung disease in preterm infants colonised with Ureaplasma urealyticum", Drugs, 61, pp.1893~1899 (2001)
- Matlow A, "Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents", Antimicrob Agents Chemother, 42, pp.1290~1292 (1998)
- Grigsby PL, "Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model", Am J Obstet Gynecol, 207, pp.475.e1~475.e14 (2012)
- Oue S, "Association of gastric fluid microbes at birth with severe bronchopulmonary dysplasia", Arch Dis Child Fetal Neonatal Ed, 94, pp.F17~22 (2009)
- Kenyon SL, "Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomized trial. ORACLE Collaborative Group", Lancet, 357, pp.979~988 (2001)
- Novy MJ, "Ureaplasma parvum or Mycoplasma hominis as sole pathogens cause chorioamnionitis, preterm delivery, and fetal pneumonia in rhesus macaques", Reprod Sci, 16, pp.56~70 (2009)
- Gerber S, "Detection of Ureaplasma urealyticum in second-trimester amniotic fluid by polymerase chain reaction correlates with subsequent preterm labor and delivery", J Infect Dis, 187, pp.518~521 (2003)
- Luki N, "Comparison of polymerase chain reaction assay with culture for detection of genital mycoplasmas in perinatal infections", Eur J Clin Microbiol Infect Dis, 17, pp.255~263 (1998)
- Ray WA, "Azithromycin and the risk of cardiovascular death", N Engl J Med, 366, pp.1881~1890 (2012)
- Mahon BE, "Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis", J Pediatr, 139, pp.380~384 (2001)
- Viscardi RM, "Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants:pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose", Antimicrob Agents Chemother, 57, pp.2127~2133 (2013)
- Tilelli JA, "Life-threatening bradyarrhythmia after massive azithromycin overdose", Pharmacotherapy, 26, pp.147~150 (2006)
- Kuppala VS, "Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants", J Pediatr, 159, pp.720~725 (2011)
- Viscardi RM, "Incidence of invasive ureaplasma in VLBW infants:relationship to severe intraventricular hemorrhage", J Perinatol, 28, pp.759~765 (2008)
- 박은애, "국내 기관지폐이형성증의 위험인자 및 예측", Neonatal medicine, 20(3), pp.290~297 (2013), 대한신생아학회
- Committee on Practice Bulletins-Obstetrics, "Practice bulletins No. 139: premature rupture of membranes", Obstet Gynecol, 122, pp.918~930 (2013)